Paraneoplastic neuromyelitis optica spectrum disorder with dual AQP4-IgG and CRMP5 antibodies following thymectomy: a case report.

Two cases with overlapping features of multiple sclerosis and neuromyelitis optica spectrum disorder.

Nationwide prevalence and incidence of MOG antibody-associated disease (MOGAD) in Denmark.

Divergent comorbidity profiles in neuromyelitis optica spectrum disorder and multiple sclerosis: A large single-centre cohort from Turkey.

Intractable Nausea as the Initial Presentation of Neuromyelitis Optica.

Case Report: Rare co-occurrence of NMOSD and capillary leak syndrome treated with satralizumab.

Pregnancy before and after NMOSD diagnosis: a retrospective study highlighting the challenges in a referral center in Brazil.

Balint syndrome as the initial presentation of neuromyelitis optica spectrum disorder.

Case Report: Recurrent sinus arrest induced by repeated vomiting.

Human umbilical cord mesenchymal stromal cells therapy for neuromyelitis optica spectrum disorder: a phase 1/2a trial.

Frequency of AQP4 and MOG Antibodies in Patients With Optic Neuritis Fulfilling Minimal New Multiple Sclerosis MRI Criteria.

Real-world safety of satralizumab in neuromyelitis optica spectrum disorder: a FAERS-based risk stratification study.

Early anti-C5 therapy in NMOSD: rationale and clinical evidence.

EEG biomarkers of microstructural damage in normal-appearing white matter among patients with neuromyelitis optica spectrum disorder: A DTI-EEG combined study.

CAR T cell therapy in autoantibody-mediated neurological disorders: a promising strategy.

Impact of Anti-CD20 Therapies on Cytokine, Chemokine and Adhesion Molecule Dynamics in Multiple Sclerosis: A Narrative Review.

Prevalence and Relative Proportions of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the Republic of Korea.

Risk Stratification and Ventilator Liberation in Neuromyelitis Optica Spectrum Disorder-Related Central Respiratory Failure.

Neuromyelitis Optica Spectrum Disorder in a Pediatric Patient Following Haploidentical Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.

Aberrant bone marrow granulopoiesis generates neutrophils that promote B cell activity in neuromyelitis optica spectrum disorder.

Low Incidence of Relapses After Vaccination in Anti-Aquaporin-4 Antibody-Positive NMOSD.

Protein A immunoadsorption for refractory neuromyelitis optica spectrum disorder: A prospective single-center study.

Relapse risk factors in double seronegative neuromyelitis optica spectrum disorder: Insights from a multicenter study.

Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases.

Intrathecal immunoglobulin production in the diagnosis, prognosis, and monitoring of autoimmune diseases of the central nervous system.

Optical Coherence Tomography Changes in Central Nervous System Inflammatory Demyelinating Diseases: A Longitudinal Retrospective Study.

Isolated Sixth Cranial Nerve Palsy as the First Presenting Sign of MOG Antibody-Associated Disease in a Three-Year-Old Child.

Microstructure-informed deep learning improves thalamic atrophy segmentation and clinical associations in multiple sclerosis and related neuroimmunological diseases.

Clinical, radiological, and CSF features distinguishing spinal dural arteriovenous fistula from idiopathic transverse myelitis and seropositive NMOSD-/MOGAD-associated myelopathy: a retrospective observational study.

Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Trident Sign in Neuromyelitis Optica Spectrum Disorder.

Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial.

ACSL4-mediated astrocyte ferroptosis augments neuroinflammation and exacerbates NMOSD pathology.

Prognosis biomarkers in MOGAD: What can we learn from observational studies?

Consistent Detection of Aquaporin-4 Antibodies: A Comparative Analysis Between Fixed and Live Cell-Based Assays.

The temporal sequence of myasthenia gravis and neuromyelitis optica spectrum disorder: a case report and systematic review of 74 patients.

ACR Appropriateness Criteria® Demyelinating Diseases.

Safety of breastfeeding under monoclonal antibodies in the offspring of mothers with multiple sclerosis or neuromyelitis optica spectrum disorder.

Aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) complicated with acute pancreatitis: A case report.

Optic neuropathies induced by immune checkpoint inhibitors: A case series and systematic review of the literature.

Efficacy and Safety of Rituximab Versus Inebilizumab in Patients With Neuromyelitis Optica Spectrum Disorder: A Dual-Center, Real-World Cohort Study.

Neuropathic Pain in Neuromyelitis Optica Spectrum Disorders: Prevalence and Management Strategies-A Systematic Review and Meta-Analysis.

Major depressive disorder in multiple sclerosis and AQP4-antibody positive neuromyelitis optica spectrum disorder: A cross-sectional study on clinical correlates in Iranian patients.

Rare demyelinating diseases of the central nervous system: A diagnostic and therapeutic challenge - based on the case of a young woman with MOGAD.

Comparative analysis of adverse event reporting signals between Satralizumab and Inebilizumab in neuromyelitis optica spectrum disorder: A pharmacovigilance study using the FDA Adverse Event Reporting System.

Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).

Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics.

A Modern Approach to Brown-Séquard Syndrome: A Case Report.

Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGAD.

Polymorphonuclear myeloid-derived suppressor cells inhibit natural killer cell function in neuromyelitis optica spectrum disorder via the CD155-TIGIT axis.

Monoclonal antibodies in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.

Neuromyelitis Optica Spectrum Disorder Initially Presenting With Meningitis-Like Symptoms: A Case Report.

Pseudoathetotic Pseudodystonia as a Manifestation of Isolated Medullary Demyelination in Neuromyelitis Optica Spectrum Disorder.

Exploration of the source of AQP4 antibody: Based on paired serum and cerebrospinal fluid samples from 98 patients.

C-Reactive Protein and Neurological Autoimmune Diseases: Bridging the Diagnostic and Pathogenic Gap.

Persistent parvovirus B19 DNAemia in B-cell depletion: Implications for family planning in multiple sclerosis and related disorders.

Neuromyelitis optica - a cause for longitudinally extensive transverse myelitis: a rare case report from Nepal and literature review.

Neuromyelitis optica spectrum disorder in an 11-year-old: a case report in a pediatric patient from Nepal.

Diverticular Perforation with Normal C-reactive Protein in a Patient with Neuromyelitis Optica Spectrum Disorder Receiving Satralizumab.

Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series.

Natalizumab exacerbates astrocytopathy in NMOSD via blockade of endothelial VCAM1-astrocytic integrin α4 interaction.

AQP4-IgG-Induced Astrocyte-Derived Small Extracellular Vesicles Carrying Mitochondrial DNA Regulate the TLR9/MyD88/NF-κB Pathway to Drive Microglial Activation and Neuromyelitis Optica.

Long-term Indian optic neuritis study (THE LION STUDY): clinical, imaging features and visual behavior of optic neuritis in Indian population over two decades.

Quantitative ophthalmic posterior segment optical coherence tomography angiography and neurologic conditions: a review.

An Unusual Case of Hypersomnolence.

Biomarkers for satralizumab treatment in neuromyelitis optica spectrum disorders: a prospective case series.

Associations between personality traits and cognitive function in multiple sclerosis and neuromyelitis optica spectrum disorder: A cross-sectional study.

The immunoproteasome as a neuroimmune hub in the central nervous system: from proteostasis stress to inflammatory pathology.

First demyelinating attack in children: A twelve year single center cohort.

Anti-IL-6 Receptor Antibody Suppresses Visual Dysfunction in AQP4 Peptide-Immunized Mice.

Demographic and Epidemiological Profile of Optic Neuritis in Colombia: A Retrospective Study Using Data from the Comprehensive Information System for Social Protection.

Double-seronegative neuromyelitis optica: it is not possible to interrupt treatment after 10 years of stability.

Double-seronegative neuromyelitis optica: it is possible to interrupt treatment after 10 years of stability.

[Neuromyelitis optica spectrum disorder with positive aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibodies].

Comparative Effectiveness of Disease-Modifying Treatments in Double Seronegative Neuromyelitis Optica Spectrum Disorder.

Age, Low Immunoglobulin G, and M Serum Levels Predict Infections in People With AQP4-IgG+ NMOSD Treated With Rituximab-A Multicenter Cohort Study From the German Neuromyelitis Optica Study Group (NEMOS).

Activation status of astrocytes drives the MS/NMOSD therapeutic paradox: Insights from IFNAR1 signaling.

Microbial-Immune Interplay in CNS Autoimmune Diseases: Lessons from Animal Models and Clinical Studies.

Natural killer cell reduction and dysfunction define a pathogenic and diagnostic axis in neuromyelitis optica spectrum disorder.

Bilateral optic neuritis preceding a Baló concentric sclerosis lesion: A case report and literature review.

Evaluation of blood-brain barrier integrity and clinical characteristics in autoimmune glial fibrillary acidic protein astrocytopathy.

Predictive factors for immunosuppression-associated severe and opportunistic infections in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Diagnostic biomarkers for differentiating AQP4-IgG- negative NMOSD from other nervous system autoimmune disorders: a retrospective study.

Demographic and clinical characteristics of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder in Canadian adults.

Isolated Paramedian Pontine Reticular Formation (PPRF) syndrome in AQP4 antibody-positive neuromyelitis optica spectrum disorder: a case report.

Case Report: Organizing pneumonia associated with AQP4-antibody neuromyelitis optica spectrum disorder in children.

Double Anti-NMO and Anti-MOG Positivity in a Patient With Metastatic Renal Carcinoma: First Reported Case.

The impact of relapse on patient disability, clinical outcomes, and subsequent burdens to patients with neuromyelitis optica spectrum disorder and caregivers.

Outcomes and predictors of relapse and severe pneumonia in Chinese patients with AQP4-IgG-positive neuromyelitis optica spectrum disorder receiving inebilizumab: a prospective cohort study.

Hearing Loss in Neuromyelitis Optica Spectrum Disorder: Case Report and Systematic Review.

Changes in Blood Cells and Complements During Relapse Prevention Therapies for Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder.

Unexpected pregnancy in a patient with AQP4-IgG + NMOSD after treatment with inebilizumab: a case report.

Therapeutic effects of IGF-2 on NMOSD by inhibiting astrocyte apoptosis through modulation of the IGF-1R/PI3K/AKT signaling pathway.

Tongue atrophy following unexplained nausea, vomiting, and hiccups.

Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines.

AQP4-IgG and mood disorders: Case series of neuromyelitis optica spectrum disorder.

Low prevalence of inflammatory bowel disease among patients with seropositive neuromyelitis optica spectrum disorder in two large referral centers.

Baseline severe disability as a predictor of treatment escalation to rituximab in AQP4-IgG-positive NMOSD patients: A retrospective cohort study.

Neurological and paraclinical features differentiating Systemic lupus erythematosus, Sjögren's disease, and neuromyelitis optica spectrum disorders.

Dysregulated Tfh/B cells and their interactions in neuromyelitis optica spectrum disorder.

Ravulizumab in NMOSD with associated interstitial pneumonitis in a 59-year-old female patient: a case report.

Efficacy of fresh frozen plasma and human albumin in therapeutic plasma exchange for refractory neuromyelitis optica spectrum disorders and multiple sclerosis exacerbation: A two-tertiary care center study.

Neuromyelitis Optica Spectrum Disorder Developing after COVID-19 Vaccination Managed with Long-Term Eculizumab Treatment: A Case Report.

Dermatomal pruritus as a heralding symptom in AQP4-positive LETM with anti-Ro52 positivity.

Urinary Tract Infection Masquerading as a Neuromyelitis Optica Spectrum Disorder Exacerbation: A Case Report.

Prognostic Modeling for the Failure of Intravenous Methylprednisolone and the Risk of Visual Disability in AQP4-IgG Positive NMOSD-ON.

Pain in NMOSD is not always neuropathic: multifocal avascular osteonecrosis mimicking neuropathic pain.

Relapse-related outcomes in the Danish population-based AQP4- antibody seropositive neuromyelitis optica spectrum disorder cohort.

The future unfolded: CAR T cells and the transformation of treatment algorithms in autoimmune neurology.

Immunotherapies for neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.

The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases.

Investigating the Frequency and Outcome of Central Vein Sign and Paramagnetic Rim Lesions in Children With MOGAD.

Outcomes of Children With Optic Neuritis as Their First Demyelinating Event.

Eculizumab as a rescue therapy in acute-phase aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder.

Myelitis-Predominant Aggressive Phenotype: Unveiling Unique Patterns of Late-Onset Neuromyelitis Optica Spectrum Disorders.

Persistent Pathological Yawning due to Neuromyelitis Optica Spectrum Disorder.

Real-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder.

OCT-Based Differentiation of First Acute Optic Neuritis: An International Study of 111 Patients With NMOSD and MOGAD.

Patient Preferences for Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatments: Results from a Discrete Choice Experiment Study in the USA.

Aquaporin-4-IgG positive radiologically isolated neuromyelitis optica spectrum disorder: treat or observe?

Astrocyte-derived extracellular vesicles as antigen-specific therapy for neuromyelitis optica spectrum disorder in the mouse model.

Folate metabolism disorder presenting as an opticospinal syndrome.

Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments.

Cerebrospinal Fluid Autoantibody Profiles in Rheumatologic Disorders Affecting the Central Nervous System: A Systematic Review.

Remnant cholesterol and lipid ratios predict the relapse of neuromyelitis optica spectrum disorder.

Screening for Biotinidase deficiency in children with spinal cord demyelination.

Apathy in patients with Neuromyelitis Optica Spectrum Disorder.

CAR T cells as novel therapeutic strategy for multiple sclerosis and other neuroimmune disorders.

Prescription Drug Use in NMOSD: A Population-Based Study in Greece with Estimation of National Disease Administrative Prevalence.

Glymphatic dysfunction in neuromyelitis optica spectrum disorder.

Optimizing kappa free light chain index thresholds for multiple sclerosis (MS) diagnosis in low-MS prevalence regions: Insights from an Asian cohort.

Glymphatic transport and ocular diseases.

Cerebellar microstructural and functional connectivity changes in patients with neuromyelitis optica spectrum disorders and their correlation with cognitive function: a female-dominated multimodal MRI study.

The Optic Nerve as a New Diagnostic Frontier in Multiple Sclerosis: How the 2024 McDonald Criteria Leverage Multimodal Evaluation for Earlier Diagnosis.

Mitochondrial-Immune Overlap in Leber Hereditary Optic Neuropathy: A Case Report and Lessons Learned.

Serum Aquaporin-4 Antibody Status and TGF-β in Neuromyelitis Optica Spectrum Disorder: Impact on Astrocyte Function and Correlation with Disease Activity and Severity.

Complement C4d Informs the Differential Diagnosis of Inflammatory Demyelinating CNS Diseases.

Progression Independent of Relapse Activity in Aquaporin-4-IgG-Positive NMOSD: A Decade-Long Cohort Study.

Neuromyelitis Optica Spectrum Disorder Presenting With Longitudinally Extensive Transverse Myelitis and Pontine Involvement in a Patient With Systemic Lupus Erythematosus.

The impact of physical and psychological health outcomes on stigma in people with neuromyelitis optica spectrum disorder: A cross-sectional study.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Mechanisms, Syndromes, and Management.

Neuromyelitis Optica Spectrum Disorder.

Autoimmune thyroid disease and human health: a systematic review of Mendelian randomization studies.

Cognitive performances in people with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.

Progressive Cerebral Atrophy and Cognitive Decline Without Cerebral Lesion in Neuromyelitis Optica Spectrum Disorder: A Case Report.

Drug-Induced Lupus Erythematosus After 14 Years of Carbamazepine Use in a Patient With Neuromyelitis Optica Spectrum Disorder: A Case Report.

Very-Late-Onset Neuromyelitis Optica Spectrum Disorder Presenting as Isolated Optic Neuritis in an 85-Year-Old Woman: A Diagnostic and Management Challenge.

Complement activation in immunological neurological disorders: mechanisms and therapeutic strategies.

Brain atrophy in NMOSD and MOGAD: a meta-analysis of volumetric and DTI biomarkers.

Impact of Autoantibody Status on Visual Outcomes in Severe Optic Neuritis Patients Without Multiple Sclerosis.

Anti-SRP antibody-positive polymyositis complicated by neuromyelitis optica spectrum disorder: a case report and literature review.

Multifocal Presentations of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Case Series From a District General Hospital in South East England.

Efficacy of a fixed-interval, body surface area-adjusted rituximab regimen in Singaporean patients with CNS inflammatory demyelinating diseases.

Multiple sclerosis research in 2025: earlier diagnosis and halting progression.

Tocilizumab in Refractory Neuro Myelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease - Experience from a Tertiary Care Centre.

Short and Long-Term Effects of Intravenous Methylprednisolone and Plasma Exchange Combination in NMOSD Attacks.

Satralizumab treatment in adults with aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder in clinical practice.

Cellular therapy in neuromyelitis optica spectrum disorder.

Brain volumetry and spinal cord imaging in patients with AQP4-IgG+ NMOSD-a systematic review and meta-analysis.

Inflammatory transcriptomic signatures in a human cellular NMOSD model reveal upregulation of NF-κB and IL6 pathways.

Cognitive impairment and multiparametric brain MRI in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder.

Decoding tRNA dynamics in neuroimmune disorders: mechanistic insights, diagnostic innovations, and therapeutic opportunities.

Alterations in the Expression of Let-7i, miR-21-5p, and miR-30b-5p in Plasma-Derived Extracellular Vesicles as the Possible Prognostic Markers in Central Demyelinating Diseases.

Evaluation of the Efficacy and Safety of Satralizumab in a Pregnant NMOSD Patient With AQP4/MOG-IgG Dual Seropositive: A Case Report.

Characterizing double seronegative neuromyelitis optica spectrum disorder: A distinct subgroup or part of the continuum?

Adherence to the MIND diet and onset of neuromyelitis optica spectrum disorder: A case-control study.

Neuromyelitis Optica-Associated Acute Intermediate Uveitis.

Herpes simplex virus associated rhomboencephalitis mimicking demyelination: a case report.

Inebilizumab: Pediatric Case Series in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder.

A real-world comparative study on the efficacy and safety of tocilizumab and rituximab in patients with neuromyelitis optica spectrum disease and myelin oligodendrocyte glycoprotein antibody-associated disease.

Experience of bortezomib use in refractory autoimmune neurological disorders.

Effect of hyperbaric oxygen therapy on peripheral blood inflammatory markers in patients with neuromyelitis optica spectrum disorder: a retrospective cohort study.

Microglial estrogen receptor 1 signal designates sexual dimorphism of AQP4 antibody-induced neuroinflammation and demyelination.

Pain in neuromyelitis optica spectrum disorder: determination of prevalence and characteristics.

Atypical Neuromyelitis Optica Spectrum Disorder: A Case of Unilateral Optic Neuritis and Partial Transverse Myelitis.

Bruton Tyrosine Kinase Inhibition Limits Multiple Sclerosis Disease-Driving Inflammation While Promoting Regulatory B Cells.

Nationwide Survey of Atopic Myelitis and Plexin D1-Immunoglobulin G-Related Pain.

Peripheral blood immune inflammatory markers in neuromyelitis optica spectrum disorders.

Effects of eculizumab and rituximab on visual function, motor function and social quality in patients with NMOSD: a comparative study.

Choroidal structure differs between multiple sclerosis and neuromyelitis optica spectrum disorder: An enhanced depth imaging optical coherence tomography study.

Inebilizuma treatment for acute serum AQP4 - IgG neuromyelitis optica: Case report.

Transcriptional expression patterns of orientation dispersion index of white matter in neuromyelitis optica spectrum disorder.

CAR T Cell Therapy for Rheumatoid Arthritis.

Severe attacks and worse prognosis in patients with late-onset neuromyelitis optica spectrum disorder highlight the need for early highly effective treatment.

Beyond the optic disc: Investigating gender-based differences in optic neuritis.

Expanding Evidence of Leptomeningeal Involvement in MOGAD and Its Relevance to Its Pathophysiology.

B cell receptor repertoire reconstitution in patients with neuromyelitis optica spectrum disorder receiving B-cell depletion therapy.

Clinical features of three cases of neurosarcoidosis with a positive aquaporin-4 antibody requiring differentiation from neuromyelitis optica spectrum disorder.

Social alienation and related factors in patients with neuromyelitis optica spectrum disorder: a cross-sectional study.

Risk of hepatitis B and tuberculosis reactivation in patients with neuromyelitis optica spectrum disorder undergoing B cell depletion therapy.

Real-World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease.

Consensus recommendations for the diagnosis and management of neuromyelitis optica spectrum disorder: A Saudi expert panel review.

Dual ROCK1/2-MYLK4 Kinase Inhibition Preserves Visual Function in a Rat Model of Neuromyelitis Optica Spectrum Disorder Optic Neuritis.

Hyperperfusion Improvement: A Potential Therapeutic Marker in Neuromyelitis Optica Spectrum Disorder (NMOSD).

Double-negative NMOSD: from case report to a proposed diagnostic and therapeutic algorithm.

The real-world experience of biologics for neuromyelitis optica spectrum disorders as first-line and switched therapy.

2025 Brazilian guidelines for the management of neuromyelitis optica spectrum disorder in adults and children.

Anterograde and trans-synaptic neurodegeneration in aquaporin-4-antibody neuromyelitis optica spectrum disorder patients with a history of transverse myelitis.

Chimeric Antigen Receptor T-Cell Therapy and Autoimmune Diseases in the Nervous System.

Clinical value of plasma C1q, C3, and C4 in NMOSD and MOGAD.